Raymond James & Associates Geron Corp Transaction History
Raymond James & Associates
- $150 Billion
- Q2 2024
A detailed history of Raymond James & Associates transactions in Geron Corp stock. As of the latest transaction made, Raymond James & Associates holds 38,315 shares of GERN stock, worth $172,800. This represents 0.0% of its overall portfolio holdings.
Number of Shares
38,315
Previous 37,600
1.9%
Holding current value
$172,800
Previous $124,000
30.65%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding GERN
# of Institutions
257Shares Held
448MCall Options Held
1.91MPut Options Held
897K-
Black Rock Inc. New York, NY46.6MShares$210 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA46.2MShares$208 Million2.95% of portfolio
-
Vanguard Group Inc Valley Forge, PA31.9MShares$144 Million0.0% of portfolio
-
Vivo Capital, LLC Palo Alto, CA27.2MShares$123 Million17.06% of portfolio
-
Darwin Global Management, Ltd. St. Helier, Y923.9MShares$108 Million12.26% of portfolio
About GERON CORP
- Ticker GERN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 377,819,008
- Market Cap $1.7B
- Description
- Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hemat...